WNY Asset Management LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 2.4% during the 1st quarter, HoldingsChannel reports. The fund owned 7,944 shares of the biopharmaceutical company stock after selling 198 shares during the quarter. WNY Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $ 578,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Mizuho Securities Co. Ltd. increased its stake in Bristol-Myers Squibb by 239.0% during the first quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company stock valued at $ 25,000 after acquiring an additional 239 shares during the period. Steward Financial Group LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $ 29,000. Horan Securities Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $ 29,000. Guardian Wealth Management Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $ 32,000. Finally, Leverty Financial Group LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $ 37,000. Hedge funds and other institutional investors own 73.07% of the company stock.
A number of equities research analysts have weighed in on BMY shares. Raymond James downgraded Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a report on Friday, June 3rd. They noted that the move was a valuation call. Citigroup reaffirmed a “buy” rating and set a $ 90.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, June 3rd. Guggenheim lifted their price objective on Bristol-Myers Squibb from $ 72.00 to $ 80.00 in a report on Monday, May 2nd. Barclays boosted their target price on Bristol-Myers Squibb from $ 66.00 to $ 68.00 in a report on Monday, May 2nd. Finally, Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $ 65.00 to $ 70.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company stock. According to data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Moderate Buy” and an average target price of $ 74.27.
Shares of Bristol-Myers Squibb stock opened at $ 79.98 on Tuesday. The firm has a fifty day moving average of $ 76.03 and a two-hundred day moving average of $ 70.46. The stock has a market capitalization of $ 170.28 billion, a price-to-earnings ratio of 28.36, a PEG ratio of 1.67 and a beta of 0.49. Bristol-Myers Squibb has a 52 week low of $ 53.22 and a 52 week high of $ 80.59. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.23 and a current ratio of 1.32.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last issued its earnings results on Friday, April 29th. The biopharmaceutical company reported $ 1.96 EPS for the quarter, beating the consensus estimate of $ 1.92 by $ 0.04. The company had revenue of $ 11.65 billion during the quarter, compared to analysts’ expectations of $ 11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $ 1.74 EPS. As a group, research analysts forecast that Bristol-Myers Squibb will post 7.56 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be given a dividend of $ 0.54 per share. This represents a $ 2.16 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Thursday, June 30th. Bristol-Myers Squibb’s payout ratio is 76.60%.
In related news, EVP Sandra Leung sold 65,000 shares of the company stock in a transaction on Monday, June 6th. The shares were sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares in the company, valued at approximately $ 23,113,076.03. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Giovanni Caforio sold 30,000 shares of the company stock in a transaction on Monday, June 13th. The shares were sold at an average price of $ 74.04, for a total transaction of $ 2,221,200.00. Following the completion of the sale, the chief executive officer now owns 551,104 shares of the company stock, valued at approximately $ 40,803,740.16. The disclosure for this sale can be found here. Insiders own 0.09% of the company stock.
Bristol-Myers Squibb Company Profile: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
See Also:
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.
.